SCHEMBL5299310

SCHEMBL5299310

CCCCCCCCCCCCCc1cc[n+](C)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 1/20 0.61
▸ ESR1 P03372 2/20 0.55
▸ ADRA2A P08913 2/20 0.55
▸ ADORA3 P0DMS8 2/20 0.55
▸ TACR2 P21452 2/20 0.55
▸ SLC6A2 P23975 2/20 0.55
▸ SLC6A4 P31645 2/20 0.55
▸ SLC6A3 Q01959 2/20 0.55
▸ CYP3A4 P08684 2/20 0.55
▸ HSD17B10 Q99714 2/20 0.55
▸ KDM4E B2RXH2 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ LMNA P02545 1/20 0.55
▸ SHBG P04278 1/20 0.55
▸ TP53 P04637 1/20 0.55
▸ HSPD1 P10809 1/20 0.55
▸ ADRB3 P13945 1/20 0.55
▸ HTR2C P28335 1/20 0.55
▸ HSPE1 P61604 1/20 0.55
▸ HIF1A Q16665 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5303025 1.00 HTR2A (0.61) HTR2AESR1ADRA2AADORA3TACR2
SCHEMBL5294380 1.00 HTR2A (0.61) HTR2AESR1ADRA2AADORA3TACR2
SCHEMBL5304765 1.00 HTR2A (0.61) HTR2AESR1ADRA2AADORA3TACR2
SCHEMBL10645352 1.00 HTR2A (0.61) HTR2AESR1ADRA2AADORA3TACR2
SCHEMBL5296180 1.00 HTR2A (0.61) HTR2AESR1ADRA2AADORA3TACR2
SCHEMBL5299615 1.00 HTR2A (0.61) HTR2AESR1ADRA2AADORA3TACR2
SCHEMBL5815570 1.00 HTR2A (0.61) HTR2AESR1ADRA2AADORA3TACR2
SCHEMBL5299368 1.00 HTR2A (0.61) HTR2AESR1ADRA2AADORA3TACR2
SCHEMBL5305758 1.00 HTR2A (0.61) HTR2AESR1ADRA2AADORA3TACR2
SCHEMBL4888088 1.00 HTR2A (0.61) HTR2AESR1ADRA2AADORA3TACR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016094226-A1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS GLYCOREGIMMUNE, INC. (US) 2016-06-16 — — WO disclosed
US-20160158258-A1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS ALTIUM GROWTH FUND, LP 2016-06-09 — — US disclosed
WO-2007006418-A1 IONIC-LIQUID-CONTAINING PRODUCTS FOR DYEING AND/OR BRIGHTENING KERATIN FIBRES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2007-01-18 — — WO disclosed
WO-2006131234-A1 COSMETIC COMPOSITIONS COMPRISING IONIC LIQUIDS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2006-12-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160158258-A1 PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS RXRA, RXRG, CX3CR1 HTR2A 771/4885ESR1 1835/4885ADRA2A 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback